Logotipo del repositorio
Logotipo del repositorio
 

Consenso colombiano basado en evidencia y en la opinión de expertos para la utilización de los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT-2) en el continuo cardiorrenal de pacientes con enfermedad renal crónica

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorMONTEJO, JUAN DIEGO
dc.contributor.authorLopera, John Mauricio
dc.contributor.authorROSSELLI SANMARTIN, CARLOS
dc.contributor.authorRonderos Botero, Izcay
dc.contributor.authordaza arnedo, rodrigo andres
dc.contributor.authorYama-Mosquera, Erica
dc.contributor.authorFLECHAS, jaflechas
dc.contributor.authorContreras, Kateir
dc.contributor.authorMachacón Miranda, Elkin
dc.contributor.authorHenao, Carlos
dc.contributor.authorROMERO JALLER, KATHERYNE CECILIA
dc.contributor.authorFigueroa Millán , Christian Camilo
dc.contributor.authorMejia-Garcia, Carlos Hernan
dc.contributor.authorHernández Sierra, Astrid Patricia
dc.contributor.authorGonzález Sánchez, Diego Andrés
dc.contributor.authorDE LA ESPRIELLA BADEL, VICTOR
dc.contributor.authorDávila Guerra, Miguel Ángel
dc.contributor.authorParra Serrano, Paola
dc.contributor.authorGuevara, Juan Guillermo
dc.contributor.authorUribe Betancur, José Mauricio
dc.contributor.authorCárdenas-Garzón, Karen
dc.contributor.authorZuluaga Peña, Julio Ricardo
dc.contributor.authorZuluaga, Juan Pablo
dc.contributor.authorRico-Fontalvo, Jorge
dc.date.accessioned2025-05-28T20:47:02Z
dc.date.available2025-05-28T20:47:02Z
dc.date.issued2025
dc.description.abstractContexto: el tratamiento de la enfermedad renal crónica (ERC) tiene como objetivo disminuir el riesgo de progresión de la enfermedad, el surgimiento de complicaciones y el riesgo de muer te, especialmente considerando el continuo cardiorrenal. Mediante diferentes ensayos clínicos realizados con personas diabéticas y no diabéticas, así como de otros grupos de riesgo como in suficiencia cardiaca y ERC, los antidiabéticos conocidos como inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT-2, según sus siglas en inglés) han demostrado efectos beneficiosos en los resultados renales y cardiovasculares. Objetivo: establecer recomendaciones para el manejo con iSGLT-2 para pacientes con ERC. Metodología: el consenso se desarrolló en las siguientes etapas: conformación del grupo desa rrollador; definición de las preguntas objeto de investigación; búsqueda, tamización, evaluación y selección de la evidencia; elaboración de síntesis y evaluación de la evidencia; discusión en paneles formales, generación de recomendaciones y juicio de expertos; y redacción, elaboración y revisión del documento del consenso. Resultados: los 22 expertos clínicos formularon un total de 15 recomendaciones para 12 pregun tas de investigación. La certeza de la evidencia varió entre moderada y alta, basada principalmente en guías de práctica clínica, revisiones sistemáticas de la literatura, ensayos clínicos y consensos de expertos. La mayoría de las recomendaciones fueron débiles a favor.spa
dc.description.abstractBackground: The treatment of chronic kidney disease (CKD) aims to decrease the risk of disease pro gression, emergence of complications, and risk of death, especially considering the cardiorenal conti nuum. Different clinical trials conducted with diabetic and non-diabetic individuals, as well as other risk groups such as heart failure and CKD, and antidiabetic drugs known as sodium-glucose cotransporter type 2 (iSGLT-2) inhibitors have shown beneficial effects on renal and cardiovascular outcomes. Purpose: The objective of this consensus was to establish recommendations for management with iSGLT-2 by patients with CKD. Methodology: The consensus was developed in the following stages: formation of the development group; definition of the research questions; search, screening, evaluation, and selection of evidence; synthesis and evaluation of the evidence; discussion in formal panels; generation of recommendations and expert judgment; and drafting, elaboration, and revision of the consensus document. Results: The 22 clinical experts formulated 15 recommendations for the 12 research questions. The certainty of the evidence ranged from moderate to high based primarily on clinical practice guidelines, systematic literature reviews, clinical trials, and expert consensus. Most of the recommendations were weak.eng
dc.format.mimetypepdf
dc.identifier.citationMontejo Hernández JD, Lopera JM, Rosselli C, Ronderos I, Daza R, Yama-MosqueraE,et al.Consenso colombiano basado en evidencia y en la opinión de expertos para la utilizaciónde los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT-2) en el continuo cardiorrenalde pacientes con enfermedad renal crónica. Rev. Colomb. Nefrol. 2025;12(2),e938. https://doi.org/10.22265/acnef.12.2.938spa
dc.identifier.doihttp://doi.org/10.22265/acnef.12.2.938
dc.identifier.issn25005006  (Electrónico)
dc.identifier.issn23897708 (Impreso)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16631
dc.identifier.urlhttps://revistanefrologia.org/index.php/rcn/article/view/938
dc.language.isospa
dc.publisherAsociación Colombiana de Nefrología e Hipertensión Arterialspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceRevista Colombiana de Nefrologíaspa
dc.sourceVol.  12 No. 2, (2025)spa
dc.subjectEnfermedad renal crónicaspa
dc.subjectDiabetes mellitus tipo 2spa
dc.subjectInhibidores del cotransportador de sodio-glucosa 2spa
dc.subjectSíndrome cardiorrenalspa
dc.subjectConsensospa
dc.subjectTécnica Delphispa
dc.subject.keywordsChronic kidney diseaseeng
dc.subject.keywordsType 2 diabetes mellituseng
dc.subject.keywordsSodium-glucose cotransporter 2 inhibitorseng
dc.subject.keywordsCardiorenal syndromeeng
dc.subject.keywordsConsensuseng
dc.subject.keywordsDelphi techniqueeng
dc.titleConsenso colombiano basado en evidencia y en la opinión de expertos para la utilización de los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT-2) en el continuo cardiorrenal de pacientes con enfermedad renal crónicaspa
dc.title.translatedEvidence-based Colombian consensus and expert opinion regarding the use of sodium-glucose cotransporter type 2 (iSGLT-2) inhibitors in the cardiorenal continuum in patients with chronic kidney diseaseeng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. https://doi.org/10.1016/j.kint.2023.10.018eng
dcterms.referencesIndolfi C, Barilla F, Basile C, Basso C, Cantaluppi V, Capasso G, et al. Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part II: From preventive strategies to treatment of patients with cardio-renal damage. G Ital Cardiol. 2022;23(10):793- 812. http://dx.doi.org/10.1714/3881.38645eng
dcterms.referencesForeman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-90. https://doi.org/10.1016/s0140-6736(18)31694-5eng
dcterms.referencesCuenta de Alto Costo. Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia 2023. Bogotá D. C.: CAC; 2024.spa
dcterms.referencesGo AS, Chertow GM, Fan D, Mcculloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305. https://doi.org/10.1056/nejmoa041031eng
dcterms.referencesLegrand K, Speyer E, Stengel B, Frimat L, Ngueyon Sime W, Massy ZA, et al. Perceived health and quality of life in patients with CKD, including those with kidney failure: findings from national surveys in France. Am J Kidney Dis. 2020;75(6):868- 78. https://doi.org/10.1053/ j.ajkd.2019.08.026eng
dcterms.referencesYeung E, Bello AK, Levin A, Lunney M, Osman MA, Ye F, et al. Current status of health systems financing and oversight for end-stage kidney disease care: a vey. BMJ Open. 2021;11(7):e047245. https://doi.org/10.1136/bmjopen-2020-047245eng
dcterms.referencesBorg R, Carlson N, Søndergaard J, Persson F. The growing challenge of chronic kidney disease: an overview of current knowledge. Int J Nephrol. 2023;2023:9609266. https://doi.org/ 10.1155/2023/9609266eng
dcterms.referencesDel Vecchio L, Beretta A, Jovane C, Peiti S, Genovesi S. A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease. Drugs. 2021;81(13):1491-511. https://doi.org/ 10.1007/s40265-021-01573-3eng
dcterms.referencesAndrianesis V, Glykofridi S, Doupis J. The renal effects of SGLT2 inhibitors and a mini review of the literature. Ther Adv Endocrinol Metab. 2016;7(5-6):212-28. https://doi.org/10. 1177/2042018816676239eng
dcterms.referencesBrown E, Wilding JPH, Alam U, Barber TM, Karalliedde J, Cuthbertson DJ. The expan ding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Ann Med. 2021;53(1):2072-89. https://doi.org/10.1080/07853890.2020.1841281eng
dcterms.referencesPodestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines. 2023;11(2):279. https://doi.org/10.3390/ biomedicines11020279eng
dcterms.referencesAristizábal-Colorado D, Ocampo-Posada M, Rivera-Martínez WA, Corredor-Rengifo D, Rico-Fontalvo J, Gómez-Mesa JE, et al. SGLT2 inhibitors and how they work beyond the glucosuric effect. State of the art. Am J Cardiovasc Drugs. 2024;24(6):707-18. https://doi.org/ 10.1007/s40256-024-00673-1eng
dcterms.referencesDi Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new the rapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24(10):8732. https://doi.org/10.3390/ijms24108732eng
dcterms.referencesBailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acu te and chronic kidney disease. Curr Diab Rep. 2022;22(1):39-52. https://doi.org/10.1007/ s11892-021-01442-zeng
dcterms.referencesWanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empa gliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323- 34. https://doi.org/10.1056/nejmoa1515920eng
dcterms.referencesNeal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, et al. Efficacy and sa fety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjun ction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-11. https://doi.org/10.2337/dc14-1237eng
dcterms.referencesWiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57. https://doi.org/ 10.1056/nejmoa1812389eng
dcterms.referencesMcMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019;21(11):1402-11. https://doi.org/10.1002/ejhf.1548eng
dcterms.referencesPacker M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-24. https://doi.org/10.1056/nejmoa2022190eng
dcterms.referencesAnker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61. https:// doi.org/10.1056/nejmoa2107038eng
dcterms.referencesSolomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-98. https://doi.org/10.1056/nejmoa2206286eng
dcterms.referencesCannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7 %: results from the CREDENCE trial. Circulation. 2020;141(5):407-10. https://doi.org/10.1161/circulationaha.119.044359eng
dcterms.referencesHeerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46. https://doi.org/10.1056/nejmoa2024816eng
dcterms.referencesHerrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022;388(2):117-27. https://doi.org/ 10.1056/nejmoa2204233eng
dcterms.referencesYau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463-76. https://doi.org/10.1016/j.ekir.2022.04.094eng
dcterms.referencesLv J, Guo L, Wang R, Chen J. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in nondiabetic patients with chronic kidney disease: a review of recent evidence. Kidney Dis. 2023;9(5):326-41. https://doi.org/10.1159/000530395eng
dcterms.referencesDzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 pt. 1):1244-63. https://doi.org/10.1016/0002-8703(91)90694-deng
dcterms.referencesFontes-Carvalho R, Santos-Ferreira D, Raz I, Marx N, Ruschitzka F, Cosentino F. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. Eur J Prev Cardiol. 2022;29(9):1352-60. https://doi.org/10.1093/eurjpc/zwab034eng
dcterms.referencesEscalada J. SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D. Diabetes Ther. 2022;13(supl. 1):1-3. https://doi.org/10.1007/ s13300-022-01281-5eng
dcterms.referencesMcGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019;124(supl. 1):S45-52. https://doi.org/10.1016/j.amjcard.2019.10.029eng
dcterms.referencesMascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, Scisciola L, Di Meo I, Sullo MG, Rafaniello C, Sportiello L. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med. 2022 Sep 21;9:1010693. https: //doi.org/10.3389/fcvm.2022.1010693eng
dcterms.referencesde Val ÍI, Mercado Castillo H, Díaz Melé MC. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter type 2 inhibitors. Med Clin. 2024;163(2):101-2. https:// doi.org/10.1016/j.medcli.2024.01.025eng
dcterms.referencesMinisterio de Salud y Protección Social. Guía metodológica para la elaboración de guías de práctica clínica con evaluación económica en el sistema general de seguridad social en salud colombiano. Bogotá, Colombia: Ministerio de Salud y Protección Social; 2014.spa
dcterms.referencesBrouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-42. https://doi.org/10.1503/cmaj.090449eng
dcterms.referencesOuzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4eng
dcterms.referencesWhiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34. https://doi.org/10.1016/j.jclinepi.2015.06.005eng
dcterms.referencesHiggins J, Green S, editores. Cochrane handbook for systematic reviews of interven tions. Versión 5.1.0 [internet]. The Cochrane Collaboration; 2011 [citado 2024 Jun 10]. https://training.cochrane.org/handbookeng
dcterms.referencesGarcía Valdés M, Suárez Marín M. El método Delphi para la consulta a expertos en la investigación científica. Rev Cub Salud Pública. 2013;39(2):253-67.spa
dcterms.referencesManterola C, Asenjo-Lobos C, Otzen T. Jerarquización de la evidencia. Niveles de eviden cia y grados de recomendación de uso actual. Rev Chil Infectol. 2014;31(6). http://dx.doi.org/ 10.4067/S0716-10182014000600011spa
dcterms.referencesAlonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016. https:// doi.org/10.1136/bmj.i2016eng
dcterms.referencesPage MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160eng
dcterms.referencesRoddick AJ, Wonnacott A, Webb D, Watt A, Watson MA, Staplin N, et al. UK Kidney Association Clinical Practice Guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibi tion in adults with kidney disease 2023 update. BMC Nephrol. 2023;24(1):310. https://doi.org/ 10.1186/s12882-023-03339-3eng
dcterms.referencesNuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-801. https://doi.org/10.1016/ s0140-6736(22)02074-8eng
dcterms.referencesLevin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. https://doi.org/10.1016/j.kint.2023.10.016eng
dcterms.referencesLiew A, Lydia A, Matawaran BJ, Susantitaphong P, Tran HTB, Lim LL. Practical conside rations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement. Nephrology. 2023;28(8):415-24. https://doi.org/10.1111/nep.14167eng
dcterms.referencesCorrea-Rotter R, Rosas-Guzmán J, Méndez-Durán A, Sebastián-Díaz MA, Díaz-Avendaño OC, Mehta-Pravin R, et al. Documento de consenso sobre el uso de iSGLT2 en pacientes con enfermedad renal crónica y diabetes. Gac Med Mex. 2022;158(M2):M1-12. https://doi.org/ 10.24875/GMM.M21000595spa
dcterms.referencesLi N, Lv D, Zhu X, Wei P, Gui Y, Liu S, et al. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Front Med. 2021;8:728089. https:// doi.org/10.3389/fmed.2021.728089eng
dcterms.referencesReyes-Farias CI, Reategui-Diaz M, Romani-Romani F, Prokop L. The effect of sodium glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS One. 2023;18(11):e0295059. https://doi.org/10.1371/journal.pone. 0295059eng
dcterms.referencesChen X, Wang J, Lin Y, Yao K, Xie Y, Zhou T. Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients. Front Endocrinol. 2023;14:1236404. https://doi.org/10.3389/fendo.2023.1236404eng
dcterms.referencesChen HB, Yang YL, Yu TH, Li YH. SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol. 2022;936:175354. https://doi.org/10.1016/ j.ejphar.2022.175354eng
dcterms.referencesAli MU, Mancini GBJ, Fitzpatrick-Lewis D, Lewis R, Jovkovic M, Zieroth S, et al. The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 recep tor agonists on cardiorenal outcomes: systematic review and meta-analysis. Can J Cardiol. https://doi.org/10.1016/j.cjca.2022.05.011eng
dcterms.referencesCao H, Rao X, Jia J, Yan T, Li D. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney di sease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2023;60(3):325-35. https://doi.org/10.1007/s00592-022-01989-7eng
dcterms.referencesShiau CH, Tsau LY, Kao CC, Peng YC, Bai CH, Wu JC, et al. Efficacy and safety of sodiumglucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2024;56(4):1359-81. https://doi.org/10.1007/ s11255-023-03789-6eng
dcterms.referencesLi LF, Ding LL, Zhan ZL, Qiu M. Meta-analysis on the safety and cardiorenal efficacy of SGLT2 inhibitors in patients without T2DM. Front Cardiovasc Med. 2021;8:690529. https:// doi.org/10.3389/fcvm.2021.690529eng
dcterms.referencesLin DSH, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, et al. Differential effects of sodiumglucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals. Eur J Endocrinol. 2023;189(1):S17-25. https://doi.org/10.1093/ejendo/lvad078eng
dcterms.referencesObrador GT, Álvarez-Estévez G, Bellorín E, Bonnano-Hidalgo C, Clavero R, Correa-Rotter R, et al. Documento de consenso sobre nuevas terapias para retrasar la progresión de la enfermedad renal crónica con énfasis en los iSGLT-2: implicaciones para Latinoamérica. Nefro Latinoam. 2024;21:1-19. https://bonga.unisimon.edu.co/10.24875/NEFRO.M24000037spa
dcterms.referencesKrishnan A, Shankar M, Lerma EV, Wiegley N, GlomCon Editorial Team. Sodium glucose cotransporter 2 (SGLT2) inhibitors and CKD: are you a #flozinator? Kidney Med. 2023;5(4):100608. https://doi.org/10.1016/j.xkme.2023.100608eng
dcterms.referencesTornero Molina F, Portilla Franco ME, Tornero Romero FJ, Herrero Calvo JA. Fragilidad y sarcopenia en la enfermedad renal crónica. Nefrología al Día. 2023:567.spa
dcterms.referencesLee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630-41. https://doi.org/10.1111/obr.12755eng
dcterms.referencesAbdul Wahab R, Cohen RV, le Roux CW. Recent advances in the treatment of patients with obesity and chronic kidney disease. Ann Med. 2023;55(1):2203517. https://doi.org/10.1080/ 07853890.2023.2203517eng
dcterms.referencesYen FS, Wang SI, Hsu CC, Hwu CM, Wei JCC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024;7(6):e2416578. https://doi.org/10.1001/jamanetworkopen.2024.16578eng
dcterms.referencesNeuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450-62. https://doi.org/10.1161/circulationaha.123.067584eng
dcterms.referencesde Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Asso ciation (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-90. https://doi.org/10.2337/dci22-0027eng
dcterms.referencesPitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovas cular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-63. https://doi.org/10.1056/nejmoa2110956eng
dcterms.referencesBakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29. https://doi.org/10.1056/nejmoa2025845eng
dcterms.referencesNeuen BL, Jardine MJ. SGLT2 inhibitors and finerenone: one or the other or both? Nephrol Dial Transplant. 2022;37(7):1209-11. https://doi.org/10.1093/ndt/gfac046eng
dcterms.referencesRossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36-45. https://doi.org/10.1016/ j.ekir.2021.10.008eng
dcterms.referencesTsukamoto S, Morita R, Yamada T, Urate S, Azushima K, Uneda K, et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibi tors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;194:110161. https://doi.org/10.1016/j.diabres.2022.110161eng
dcterms.referencesHeerspink HJL, Vart P, Jongs N, Neuen BL, Bakris G, Claggett B, et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023;25(11):3327-36. https://doi.org/10.1111/dom.15232eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
1.61 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca